tradmap

GLAS Glass House Brands Inc.

$2.32 -0.85%

Data as of close

Healthcare · Medicinal Chemicals & Botanical Products

Glass House Brands Inc. (GLAS) is a healthcare company in the Medicinal Chemicals & Botanical Products industry, with a market capitalization of $190 million. Shares last traded at $2.32. Net profit margin is -16.3%, below the peer median of -8.8%. Revenue declined 9.4% year over year.

Market Cap
$190M
Shares Out
81.9M
EPS (TTM)
-$0.55
P/E (TTM)*
—
P/S Ratio
1.04
P/B Ratio
2.57
Dividend / Share
—
Dividend Yield
—
52-Week High
—
52-Week Low
—
Volume (venue)
34,943
Avg Vol (3m, venue)
42,022.143

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-0.64%
1M
-56.64%
3M
-74.96%
6M
—
YTD
-81.40%
1Y
—

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
20.16
SMA (50)
$5.87
SMA (200)
—
Price vs SMA50
-60.51%
Price vs SMA200
—
ATR (14)
$0.38

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$182M
Net Income
-$30M
Gross Margin
42.3%
Operating Margin
-9.1%
Net Margin
-16.3%
Return on Equity
-40.1%
Return on Assets
-9.3%
Current Ratio
1.78
Debt / Equity
0.93
Revenue Growth (YoY)
-9.4%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2025-12-31. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Medicinal Chemicals & Botanical Products peers

GLAS vs 14 industry peers (Medicinal Chemicals & Botanical Products), by market cap. Data as of close

P/S vs peers
1.04 / 0.58 med
+80% premium
Net margin vs peers
-16.3% / -8.8% med
below median
1–14 of 14
DFTXDefinium Therapeutics, Inc.$4.5B———+2.93%
RGCRegencell Bioscience Holdings Ltd$3.0B———-2.55%
TRLVTrulieve Cannabis Corp.$2.2B—1.95-41.8%+3.78%
CRONCronos Group$1.2B17.826.9639.1%+1.04%
TLRYTilray Brands$393M—0.41-17.1%+4.72%
SNDLSNDL Inc.$354M———+5.08%
CGCCanopy Growth$301M—1.43-80.0%+4.42%
ACBAurora Cannabis$290M———+22.16%
USNAUSANA HEALTH SCIENCES INC$275M—0.30-2.4%+1.16%
GLASGlass House Brands Inc.$190M—1.04-16.3%-0.85%
NAGENiagen Bioscience, Inc.$187M11.681.4512.4%-1.67%
MDWDMediWound Ltd.$173M———-0.52%
FTLFFITLIFE BRANDS, INC.$76M12.190.756.2%-2.06%
BTMDbiote Corp.$32M5.530.183.2%-0.44%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.